Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F19%3A10406876" target="_blank" >RIV/00216208:11110/19:10406876 - isvavai.cz</a>
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9VlywRcLf6" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9VlywRcLf6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1182/blood-2018-03-839688" target="_blank" >10.1182/blood-2018-03-839688</a>
Alternative languages
Result language
angličtina
Original language name
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab
Original language description
Most patients with chronic lymphocytic leukemia (CLL) are elderly (70% are older than age 65 years ) and unfit, often with 1 or more comorbidities, thus making them ineligible for intensive chemoimmunotherapy regimens such as rituximab plus fludarabine and cyclophosphamide. The pivotal CLL11 trial (NCT01010061) established obinutuzumab (GA101 [G]; a type II, glycoengineered, anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity and improved direct B-cell killing ) plus chlorambucil (Clb) as a new standard of care for previously untreated CLL patients with comorbidities. In CLL11, G-Clb demonstrated a greater effect on progression-free survival (PFS) and overall survival (OS) vs rituximab plus chlorambucil (R-Clb) and vs Clb alone.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood
ISSN
0006-4971
e-ISSN
—
Volume of the periodical
133
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
494-497
UT code for WoS article
000457340200014
EID of the result in the Scopus database
2-s2.0-85060817034